HLS Therapeutics (TSE:HLS) Trading Down 0.6%

HLS Therapeutics Inc. (TSE:HLS) shares were down 0.6% during trading on Tuesday . The stock traded as low as C$3.24 and last traded at C$3.24. Approximately 3,040 shares traded hands during trading, a decline of 88% from the average daily volume of 25,268 shares. The stock had previously closed at C$3.26.

Analyst Ratings Changes

Separately, Stifel Nicolaus reduced their price target on HLS Therapeutics from C$3.75 to C$3.25 in a research report on Tuesday, August 13th.

HLS Therapeutics Trading Down 0.6 %

The firm has a market cap of C$103.00 million, a P/E ratio of -3.18 and a beta of 1.04. The firm has a fifty day simple moving average of C$3.26 and a 200-day simple moving average of C$3.78. The company has a debt-to-equity ratio of 100.44, a current ratio of 2.02 and a quick ratio of 1.01.

HLS Therapeutics (TSE:HLS) last issued its earnings results on Thursday, August 8th. The company reported C($0.25) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of C($0.25). The company had revenue of C$19.87 million for the quarter, compared to analysts’ expectations of C$19.25 million. HLS Therapeutics had a negative return on equity of 24.82% and a negative net margin of 40.90%. On average, equities research analysts expect that HLS Therapeutics Inc. will post -0.12 earnings per share for the current year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.